logo
Plus   Neg
Share
Email

Novartis Reports EC Approval Of Xolair Syringe For Self-administration

Novartis announced the European Commission has approved Xolair (omalizumab) prefilled syringe for self-administration, allowing patients with severe allergic asthma and chronic spontaneous urticaria to administer their own treatment.

The company noted that Xolair, which targets immunoglobulin E, is the first and only biologic to be approved in the European Union, Iceland, Norway, and Liechtenstein for self-administration (or administration by a trained caregiver) for the treatment of severe allergic asthma in patients 6 years of age and older that have difficulty in controlling their asthma symptoms and for chronic spontaneous urticaria in patients 12 years of age and older who continue to have hives that are not controlled by H1 antihistamines.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
erman software giant SAP SE announced the launch of its blockchain-based supply chain tracking system that helps eliminate counterfeit drugs along the pharmaceutical supply chain. In a statement, the company noted that its blockchain-based solution helps customers comply with the U.S. Drug Supply Chain Security Act or DSCSA. A measure reflecting UK households' perceptions regarding their finances in the coming 12 months remained subdued and they continue expect further deterioration in finances this year, survey data from IHS Markit showed on Monday. The IHS Markit UK household finance index rose to a three-month high... Saudi Arabia and the United Arab Emirates have joined together to launch a new cryptocurrency, according to UAE's national press agency WAM. The Saudi-Emirati Coordination council, during its first meeting in Abu Dhabi, launched its Strategy of Resolve with seven initiatives in vital sectors for collaboration between both countries, including the Saudi-Emirati Pilot cryptocurrency.
Follow RTT